Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Statistical Measurement
Statistical Measurement [Domain]
Prepaid expenses
Increase (Decrease) in Prepaid Expense
Non-cash royalty revenue related to sale of future royalties
Non-cash Royalty Revenue Related to Sale of Future Royalties
Non-cash Royalty Revenue Related to Sale of Future Royalties
Microchips Biotech, Inc.
Microchips Biotech, Inc. [Member]
Microchips Biotech, Inc. [Member]
Cover [Abstract]
Weighted Average Remaining Life in Years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Net change in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Schedule of Future Minimum Lease Payments
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Trading Symbol
Trading Symbol
All Trading Arrangements
All Trading Arrangements [Member]
Options exercisable (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Grant Date Fair Value
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Net Income [Text Block]
Non-NEOs
Non-NEOs [Member]
Additions to property and equipment and reduction of deposits
Additions To Property And Equipment And Reduction To Deposits
Additions To Property And Equipment And Reduction To Deposits
Rule 10b5-1 Arrangement Adopted
Rule 10b5-1 Arrangement Adopted [Flag]
Awards Close in Time to MNPI Disclosures
Awards Close in Time to MNPI Disclosures [Table]
Square footage of office space
Net Rentable Area
Pay vs Performance Disclosure [Line Items]
License and Collaboration Agreement
License And Collaboration Agreement [Member]
License And Collaboration Agreement [Member]
Peer Group Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Amended and Restated 2014 Stock Incentive Plan
Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member]
Amended And Restated Two Thousand Fourteen Stock Incentive Plan
Milestone payments, contingent amount
Milestone Payments, Contingent Amount
Milestone payments, contingent amount.
Weighted Average Remaining Contractual Term (Years)
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Roll Forward]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term
Organization and Description of Business
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Operating lease liabilities
Increase (Decrease) in Operating Lease Liability
Non-Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Award Timing Disclosures [Line Items]
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. [Member]
Pear Tree Pharmaceuticals, Inc.
Other Performance Measure, Amount
Other Performance Measure, Amount
Portion at Fair Value Measurement
Portion at Fair Value Measurement [Member]
Leased Properties
Lessee, Operating Leases [Text Block]
Common stock, shares outstanding (in shares)
Beginning balance (in shares)
Ending balance (in shares)
Common Stock, Shares, Outstanding
Non-cash lease expenses
Operating Lease, Cost
Other receivables
Other Receivables, Net, Current
Interest payable
Increase (Decrease) in Interest Payable, Net
Class of Warrant or Right
Class of Warrant or Right [Axis]
March 2023 At The Market Sales Agreement
March 2023 At The Market Sales Agreement [Member]
March 2023 At The Market Sales Agreement
Lease liabilities long-term
Operating Lease, Liability, Noncurrent
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrant term
Warrants and Rights Outstanding, Term
Plan Name
Plan Name [Domain]
Other non-current assets
Other Assets, Noncurrent
Entity Tax Identification Number
Entity Tax Identification Number
Leases [Abstract]
Leases [Abstract]
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Grant, DARE-PTB1
Grant, DARE-PTB1 [Member]
Grant, DARE-PTB1
Interest rate on insurance financing
Insurance Financing, Interest Rate
Insurance Financing, Interest Rate
Net cash provided by (used in) operating activities
Net Cash Provided by (Used in) Operating Activities
Shares of common stock for net proceeds
Sale of Stock, Consideration Received on Transaction
Cash flows from operating activities
Net Cash Provided by (Used in) Operating Activities [Abstract]
Project [Domain]
Project [Domain]
Plan Name
Plan Name [Axis]
Prepaid expenses
Prepaid Expense, Current
Equity Components [Axis]
Equity Components [Axis]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award Timing Method
Award Timing Method [Text Block]
Trading Arrangements, by Individual
Trading Arrangements, by Individual [Table]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Insider Trading Policies and Procedures [Line Items]
Total obligation
License And Services Agreement, Total Obligation
License And Services Agreement, Total Obligation
Business Acquisition, Acquiree
Business Acquisition, Acquiree [Domain]
Adjustment to Compensation, Amount
Adjustment to Compensation Amount
Additional paid-in capital
Additional Paid in Capital, Common Stock
Compensation Amount
Outstanding Recovery Compensation Amount
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]
Entity Small Business
Entity Small Business
Company Selected Measure Amount
Company Selected Measure Amount
Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]
Proceeds from award of grants
Proceeds From Award Of Grants
Proceeds From Award Of Grants
Issuance costs
Payments of Debt Issuance Costs
Tabular List, Table
Tabular List [Table Text Block]
Level 3
Fair Value, Inputs, Level 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]
Lessee, Lease, Description [Line Items]
Lessee, Lease, Description [Line Items]
Accrued expenses
Accrued Liabilities, Current
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Proceeds from royalties received
Upfront payment from the sale of future royalties
Proceeds from Royalties Received
Class of Warrant or Right [Line Items]
Class of Warrant or Right [Line Items]
License and services agreement term
License And Services Agreement, Term
License And Services Agreement, Term
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Total cash, cash equivalents and restricted cash
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Schedule of Accounts, Notes, Loans and Financing Receivable [Table]
Accounts and Financing Receivables [Table]
July 2023 Financing
July 2023 Financing [Member]
July 2023 Financing
Royalty Interest Financing
Royalty Interest Financing [Text Block]
Royalty Interest Financing
Current assets
Assets, Current [Abstract]
Sales Milestones
Sales Milestones [Member]
Sales Milestones [Member]
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
CMF
National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell [Member]
National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell
Total payment
Research and Development Agreement, Commitment, Amount
Research and Development Agreement, Commitment, Amount
Product and Service [Domain]
Product and Service [Domain]
Employee Stock Option
Stock options
Share-Based Payment Arrangement, Option [Member]
Net proceeds from issuance of common stock and common stock warrants
Net Proceeds From Issuance Of Common Stock And Warrants
Net proceeds from issuance of common stock and warrants.
Depreciation
Depreciation
2025
Lessee, Operating Lease, Liability, to be Paid, Year One
License fee revenue
License [Member]
Additional investment amount
Class Of Warrant Or Right, Supplement Investment
Class Of Warrant Or Right, Supplement Investment
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Comprehensive income (loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Outstanding and exercisable, Weighed Average Remaining Life in Years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms
Going Concern
Going Concern [Policy Text Block]
Going Concern
Upon Achieving Certain Commercial Milestones
Upon Achieving Certain Commercial Milestones [Member]
Upon Achieving Certain Commercial Milestones [Member]
Preferred stock, shares outstanding (in shares)
Preferred Stock, Shares Outstanding
Warrants
Warrant [Member]
Other receivables
Increase (Decrease) in Other Receivables
Foundation
Foundation [Member]
Foundation
Biotherapeutic Product Grant Agreement
Biotherapeutic Product Grant Agreement [Member]
Biotherapeutic Product Grant Agreement
Award Type
Award Type [Axis]
Class of warrant or right, extent holder own percentage
Class of Warrant or Right, Extent Holder Own Percentage
Class of Warrant or Right, Extent Holder Own Percentage
Number of significant performance obligations
Revenue, Number Of Significant Performance Obligations
Revenue, Number Of Significant Performance Obligations
Related Party Transaction [Domain]
Related Party Transaction [Domain]
Basis after conversion (in shares)
Stockholders' Equity Note, Stock Split, Conversion Basis After Reverse Stock Split
Stockholders' Equity Note, Stock Split, Conversion Basis After Reverse Stock Split
Commission percent
Percentage Of Aggregate Commission
Percentage of aggregate commission.
Exercised (in usd per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Cash and Cash Equivalents
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Property and equipment, net
Property, Plant and Equipment, Net
Total liabilities
Liabilities
Class of warrant or right, exercises
Class Of Warrant Or Right, Exercises
Class Of Warrant Or Right, Exercises
CRADA
CRADA [Member]
CRADA
Exercisable (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Common stock, par value (in usd per share)
Common Stock, Par or Stated Value Per Share
Forgone Recovery, Explanation of Impracticability
Forgone Recovery, Explanation of Impracticability [Text Block]
Research and development expenses
Research and Development Expense
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Expiration Date
Trading Arrangement Expiration Date
Cash flows from investing activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
Number of Shares Underlying Warrants
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Cash flow from operations
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Royalty Purchase Agreement
Royalty Purchase Agreement [Member]
Royalty Purchase Agreement
Class of warrant or right, number of securities called by each warrant or right
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Current portion of lease liabilities
Operating Lease, Liability, Current
Total Shareholder Return Amount
Total Shareholder Return Amount
Common stock, shares issued (in shares)
Common stock, shares issued (in shares)
Common Stock, Shares, Issued
Upon Achieving Certain Clinical and Regulatory Development Milestones
Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]
Upon Achieving Certain Clinical And Regulatory Development Milestones [Member]
Entity
Entity [Domain]
Equity Awards Adjustments, Footnote
Equity Awards Adjustments, Footnote [Text Block]
Initial payment
Grants receivable
Grants Receivable
Authorized amount (up to)
Sale Of Stock, Authorized, Amount
Sale Of Stock, Authorized, Amount
Other cost
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
Number of additional payment
Royalty Agreement, Number Of Additional Payments
Royalty Agreement, Number Of Additional Payments
Class of warrant or right, holder election percentage
Class of Warrant or Right, Holder Election Percentage
Class of Warrant or Right, Holder Election Percentage
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Adopted [Flag]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Proceeds from sale of royalty and milestone rights
Proceeds From Sale Of Royalty And Milestone Rights
Proceeds From Sale Of Royalty And Milestone Rights
Sales based milestones amount
Milestone Payments, Contingent Amount, Sales Based Milestones Amount
Milestone Payments, Contingent Amount, Sales Based Milestones Amount
Exercised (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Advanced written notice period
Upfront License Fee, Advanced Written Notice, Period
Upfront License Fee, Advanced Written Notice, Period
Named Executive Officers, Footnote
Named Executive Officers, Footnote [Text Block]
Research and development
Research and Development Expense [Member]
Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Common stock, shares authorized (in shares)
Common Stock, Shares Authorized
Class of Warrant or Right [Table]
Class of Warrant or Right [Table]
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Diluted (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Bayer
Bayer Healthcare LLC [Member]
Bayer Healthcare LLC
Transaction costs
Sale Of Royalty And Milestone Rights, Net Of Transaction Costs
Sale Of Royalty And Milestone Rights, Net Of Transaction Costs
MNPI Disclosure Timed for Compensation Value
MNPI Disclosure Timed for Compensation Value [Flag]
Bayer Healthcare License Agreement
Bayer Healthcare License Agreement [Member]
Bayer Healthcare License Agreement [Member]
Total stockholders' deficit
Beginning balance
Ending balance
Equity, Attributable to Parent
Strategic Agreements
Collaborative Arrangement Disclosure [Text Block]
Related Party
Related Party [Member]
Renewal term of operating lease
Lessee, Operating Lease, Renewal Term
Fair Value, Measurements, Recurring
Fair Value, Recurring [Member]
Granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options to purchase number of outstanding shares of common stock (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Sale of Stock
Sale of Stock [Domain]
Pension Adjustments Prior Service Cost
Pension Adjustments Prior Service Cost [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
All Executive Categories
All Executive Categories [Member]
Changed Peer Group, Footnote
Changed Peer Group, Footnote [Text Block]
Weighted Average Remaining Contractual Term (Years), Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Assets
Assets [Abstract]
Outstanding beginning balance (in shares)
Outstanding ending balance (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Credits to research and development expense
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Document Type
Document Type
Pension Benefits Adjustments, Footnote
Pension Benefits Adjustments, Footnote [Text Block]
Measurement Input, Expected Dividend Payment
Measurement Input, Expected Dividend Payment [Member]
Total Shareholder Return Vs Peer Group
Total Shareholder Return Vs Peer Group [Text Block]
Non-dilutive grant funding, percentage excluded
Non-Dilutive Grant Funding, Percentage Excluded
Non-Dilutive Grant Funding, Percentage Excluded
Non-cash interest expense on liability related to sale of future royalties
Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties
Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties
Weighted Average Remaining Contractual Term (Years), Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Other income (expense)
Other Income and Expenses [Abstract]
Former Stockholders of MBI
Former Stockholders of MBI [Member]
Former Stockholders of MBI
Sildenafil Cream, 2.0%
Sildenafil Cream, 2.0% [Member]
Sildenafil Cream, 2.0%
Basis prior to conversion (in shares)
Stockholders' Equity Note, Stock Split, Conversion Basis Prior To Reverse Stock Split
Stockholders' Equity Note, Stock Split, Conversion Basis Prior To Reverse Stock Split
Subsequent Event [Table]
Subsequent Event [Table]
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Commitments and contingencies.
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Maximum
Maximum [Member]
Equity Valuation Assumption Difference, Footnote
Equity Valuation Assumption Difference, Footnote [Text Block]
Merger Agreement
Merger Agreement [Member]
Merger Agreement
Project [Axis]
Project [Axis]
Premiums, taxes and fees
Insurance Financing, Premiums, Taxes And Fees, Amount
Insurance Financing, Premiums, Taxes And Fees, Amount
Antidilutive Securities
Antidilutive Securities [Axis]
Royalty expenses
Royalty Expense
Accounts payable
Accounts Payable, Current
Accounting Policies [Abstract]
Accounting Policies [Abstract]
Revenue
Revenues [Abstract]
Sale of royalty and milestone rights, net
Royalty Income, Nonoperating
Shares issued (in usd per share)
Shares Issued, Price Per Share
Expired (in usd per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Number of experts
License Agreement, Number Of Experts
License Agreement, Number Of Experts
Fair Value of Financial Instruments
Fair Value Measurement, Policy [Policy Text Block]
Current Fiscal Year End Date
Current Fiscal Year End Date
Less: accreted interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Statistical Measurement
Statistical Measurement [Axis]
PEO Name
PEO Name
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Commitments and contingencies.
Non-Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Total Compensation Amount
Equity Award
Award Type [Domain]
Future net sales
Royalty Agreement, Future Net Sales, Percentage
Royalty Agreement, Future Net Sales, Percentage
Name
Outstanding Recovery, Individual Name
Licensing Agreements
Licensing Agreements [Member]
Expiration period
License Agreement, Expiration Period
License Agreement, Expiration Period
Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Income (Loss) Per Common Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid vs. Company Selected Measure [Text Block]
Royalty Purchase Agreements
Royalty Purchase Agreements [Text Block]
Royalty Purchase Agreements
Non-PEO NEO
Non-PEO NEO [Member]
Unamortized stock-based compensation expense
Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent
Additional paid-in capital
Additional Paid-in Capital [Member]
Award Timing Predetermined
Award Timing Predetermined [Flag]
Milestone payments, reimburse amount, PDUFA fees and other manufacturing expenses
Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses
Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses
Repayment of liability on sale of future royalties
Repayment Of Liability On Sale Future Royalties
Repayment Of Liability On Sale Future Royalties
Subsequent Event Type
Subsequent Event Type [Domain]
Class of Stock [Line Items]
Class of Stock [Line Items]
Recently Issued Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Income (loss) per common share - diluted (in usd per share)
Earnings Per Share, Diluted
Counterparty Name [Domain]
Counterparty Name [Domain]
Supplemental investment (in shares)
Class Of Warrant Or Right, Supplement Investment Share Amount
Class Of Warrant Or Right, Supplement Investment Share Amount
Name
Measure Name
2014 Employee Stock Purchase Plan
Two Thousand And Fourteen Employee Stock Purchase Plan [Member]
Two thousand and fourteen employee stock purchase plan.
Entity Interactive Data Current
Entity Interactive Data Current
Restatement does not require Recovery
Restatement Does Not Require Recovery [Text Block]
Schedule of Common Stock Warrants Outstanding
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Number of operating segments
Number of Operating Segments
Insurance Financing
Insurance Financing [Member]
Insurance Financing
XOMA
XOMA (US) LLC [Member]
XOMA (US) LLC
Preferred stock, shares issued (in shares)
Preferred Stock, Shares Issued
Performance period
Research And Development Arrangement, Performance Period
Research And Development Arrangement, Performance Period
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Weighted average amortization period
Weighted Average Amortization Period
Weighted Average Amortization Period
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Contingent Consideration Type [Domain]
Contingent Consideration Type [Domain]
Exercisable (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number
Liability related to the sale of future royalties, net
Royalty Guarantees, Commitments, Amount
Supplemental disclosure of non-cash investing and financing activities:
Supplemental Cash Flow Information [Abstract]
Total revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Maximum royalty payments
Royalty Agreement, Maximum Royalty Payments
Royalty Agreement, Maximum Royalty Payments
Milestone payments
Research And Development Milestone Payment
Research and development milestone payment.
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
Loss from operations
Loss from operations
Operating Income (Loss)
Total liabilities and stockholders' deficit
Liabilities and Equity
Deferred grant funding
Deferred Grant Funding Current
Deferred Grant Funding Current
Subsequent Events
Subsequent Events [Text Block]
Rule 10b5-1 Arrangement Terminated
Rule 10b5-1 Arrangement Terminated [Flag]
All Adjustments to Compensation
All Adjustments to Compensation [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
DARE-LARC1 2021 Grant Agreement
DARE-LARC1 2021 Grant Agreement [Member]
DARE-LARC1 2021 Grant Agreement
Significant Accounting Policies [Line Items]
Significant Accounting Policies [Line Items]
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Period of insufficient cash and liquidity requirements
Period of Insufficient Cash and Liquidity Requirements
Period of Insufficient Cash and Liquidity Requirements
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Legal Entity
Legal Entity [Axis]
Operating right-of-use assets obtained in exchange for new operating lease liabilities, net
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Issuance of note payable
Proceeds from Notes Payable
Underlying Security Market Price Change
Underlying Security Market Price Change, Percent
Measurement Input Type [Axis]
Measurement Input Type [Axis]
Individual:
Individual [Axis]
Related Party Transaction [Axis]
Related Party Transaction [Axis]
Assignment Agreement
Assignment Agreement [Member]
Assignment Agreement [Member]
Accumulated other comprehensive loss
AOCI Attributable to Parent [Member]
Schedule of Changes in the Liability Related to the Royalty Interest Financing
Schedule Of Changes In The Liability Related To The Royalty Interest Financing [Table Text Block]
Schedule Of Changes In The Liability Related To The Royalty Interest Financing
Canceled/forfeited (in usd per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Product and Service [Axis]
Product and Service [Axis]
Entity Address, State or Province
Entity Address, State or Province
Statement [Line Items]
Statement [Line Items]
Measurement Input Type [Domain]
Measurement Input Type [Domain]
Deposits
Increase (Decrease) in Deposit Assets
Erroneous Compensation Analysis
Erroneous Compensation Analysis [Text Block]
Significant Accounting Policies [Table]
Significant Accounting Policies [Table]
Significant accounting policies.
License fee expenses
License Fee Expense
License Fee Expense
Operating expenses
Operating Expenses [Abstract]
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Receivable for expenses eligible for reimbursement
Receivable For Expenses Eligible For Reimbursement
Receivable For Expenses Eligible For Reimbursement
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Outstanding beginning balance (in usd per share)
Outstanding ending balance (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Liabilities and stockholders’ deficit
Liabilities and Equity [Abstract]
Minimum
Minimum [Member]
Restatement Determination Date
Restatement Determination Date
Estimate of Fair Value Measurement
Estimate of Fair Value Measurement [Member]
Royalty revenue
Royalty [Member]
Adoption Date
Trading Arrangement Adoption Date
Pay vs Performance Disclosure
Pay vs Performance Disclosure [Table]
Warrants and rights outstanding, measurement input
Warrants and Rights Outstanding, Measurement Input
Related Party Transactions [Abstract]
Deferred revenue, non-current
Contract with Customer, Liability, Noncurrent
Outstanding beginning balance (in usd per share)
Outstanding ending balance (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Sildenafil Cream, 3.6%
Sildenafil Cream, 3.6% [Member]
Sildenafil Cream, 3.6%
Operating lease right-of-use assets
Right of use asset
Operating Lease, Right-of-Use Asset
Erroneously Awarded Compensation Recovery
Erroneously Awarded Compensation Recovery [Table]
Outstanding beginning balance (in shares)
Outstanding ending balance (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Quarterly payment period
Royalty Agreement, Quarterly Payments, Period
Royalty Agreement, Quarterly Payments, Period
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]
DARE-LARC1
DARE-LARC1 [Member]
DARE-LARC1
Clinical and Regulatory Milestones
Clinical And Regulatory Milestones [Member]
Clinical And Regulatory Milestones [Member]
Exercise Price
Award Exercise Price
Net Income (Loss) Per Share
Earnings Per Share [Text Block]
Arrangement Duration
Trading Arrangement Duration
Subsequent Event
Subsequent Event [Member]
Incremental borrowing rate, amount over prime rate
Operating Lease, Incremental Borrowing Rate, Prime Rate
Operating Lease, Incremental Borrowing Rate, Prime Rate
Stockholders' deficit
Equity, Attributable to Parent [Abstract]
Granted (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Internal rate of return
Royalty Agreement, Internal Rate Of Return
Royalty Agreement, Internal Rate Of Return
Peer Group Issuers, Footnote
Peer Group Issuers, Footnote [Text Block]
Upon Reaching Certain Worldwide Net Sales Milestones
Upon Reaching Certain Worldwide Net Sales Milestones [Member]
Upon reaching certain worldwide net sales milestones.
Right of use asset - operating lease
Increase (Decrease) In Operating Lease Right-of-Use Asset
Increase (Decrease) In Operating Lease Right-of-Use Asset
Material Terms of Trading Arrangement
Material Terms of Trading Arrangement [Text Block]
All Individuals
All Individuals [Member]
United in Endeavor, LLC
United in Endeavor, LLC [Member]
United in Endeavor, LLC
Commitments and Contingencies
Commitments Disclosure [Text Block]
PEO
PEO [Member]
Upon Achieving Certain Development Milestones
Upon Achieving Certain Development Milestones [Member]
Upon Achieving Certain Development Milestones [Member]
Name
Trading Arrangement, Individual Name
Other income (expense), net
Other Nonoperating Income (Expense)
Outstanding and exercisable, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Registered Direct Offering
Registered Direct Offering [Member]
Registered Direct Offering
Receivables [Abstract]
Receivables [Abstract]
Granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted
Maximum potential milestone payments
Maximum Potential Milestone Payments
Maximum Potential Milestone Payments
Other non-current assets
Increase (Decrease) in Other Noncurrent Assets
Percentage of royalty rate
Royalty Rate, Percentage
Royalty Rate, Percentage
Proceeds from the exercise of common stock warrants
Proceeds From Issuance Of Common Stock And Warrants
Proceeds from issuance of common stock and warrants.
Phase II Segment
Phase II Segment [Member]
Phase II Segment
MBI
MBI [Member]
MBI
Awards Close in Time to MNPI Disclosures, Table
Awards Close in Time to MNPI Disclosures [Table Text Block]
Other Commitments [Domain]
Other Commitments [Domain]
Catalent and MilanaPharm
Catalent and MilanaPharm [Member]
Catalent and MilanaPharm
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Common stock reserved for future issuance (in shares)
Common Stock, Capital Shares Reserved for Future Issuance
Measurement Input, Price Volatility
Measurement Input, Price Volatility [Member]
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]
Potential annual license maintenance fee payments, thereafter
Potential Annual License Maintenance Fee Payments, Thereafter
Potential Annual License Maintenance Fee Payments, Thereafter
Related Party
Related and Nonrelated Parties [Domain]
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Amount
Local Phone Number
Local Phone Number
Grant, ARPA-H
Grant, ARPA-H [Member]
Grant, ARPA-H
Aggregate Erroneous Compensation Not Yet Determined
Aggregate Erroneous Compensation Not Yet Determined [Text Block]
Total operating expenses
Operating Expenses
Maximum percentage increase
License And Services Agreement, Maximum Fee Increase, Percentage
License And Services Agreement, Maximum Fee Increase, Percentage
Working capital
Working Capital (Deficit)
Working Capital (Deficit)
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
PEO Total Compensation Amount
PEO Total Compensation Amount
Potential future payment
Royalty Agreement, Maximum Potential Milestone Payments
Royalty Agreement, Maximum Potential Milestone Payments
Income Statement Location
Statement of Income Location, Balance [Axis]
Licensed Product or Process for Vaginal or Urological Use
Licensed Product or Process for Vaginal or Urological Use [Member]
Licensed Product or Process for Vaginal or Urological Use
Common stock
Common stock
Common Stock [Member]
Measure:
Measure [Axis]
Sale of stock, prospectus offering amount
Sale Of Stock, Prospectus Offering Amount
Sale Of Stock, Prospectus Offering Amount
Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Stock split, conversion ratio
Stockholders' Equity Note, Stock Split, Conversion Ratio
Preferred stock, shares authorized (in shares)
Preferred Stock, Shares Authorized
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Expense of Enforcement, Amount
Issuance of common stock (in shares)
Stock Issued During Period, Shares, New Issues
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Central Index Key
Entity Central Index Key
General and administrative
General and Administrative Expense [Member]
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Table]
Non-GAAP Measure Description
Non-GAAP Measure Description [Text Block]
2022 Stock Incentive Plan
Two Thousand Twenty Two Stock Incentive Plan [Member]
Two Thousand Twenty Two Stock Incentive Plan
Non-PEO NEO Average Compensation Actually Paid Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Juniper Pharmaceuticals, Inc
Juniper Pharmaceuticals, Inc. [Member]
Juniper Pharmaceuticals, Inc. [Member]
Potential future payment, percentage
Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones
Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones
Stockholders' Equity
Equity [Text Block]
Award Timing, How MNPI Considered
Award Timing, How MNPI Considered [Text Block]
Equity Component [Domain]
Equity Component [Domain]
Preferred stock, par value (in usd per share)
Preferred Stock, Par or Stated Value Per Share
Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets:
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]
Deferred grant funding
Increase (Decrease) In Deferred Grant Funding
Increase (Decrease) In Deferred Grant Funding
Additional 402(v) Disclosure
Additional 402(v) Disclosure [Text Block]
Cash paid to stockholders' representative
Payments to Stockholders' Representative in Business Combination
Payments to Stockholders' Representative in Business Combination
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Measurement Input, Risk Free Interest Rate
Measurement Input, Risk Free Interest Rate [Member]
Entity Shell Company
Entity Shell Company
Measurement Basis [Axis]
Measurement Basis [Axis]
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Credits recorded to research and development expense for costs related to award
Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred
Revenue tier threshold, upper range limit
Royalty Agreement, Revenue Tier Threshold, Incremental Amount
Royalty Agreement, Revenue Tier Threshold, Incremental Amount
Title
Trading Arrangement, Individual Title
Statement [Table]
Statement [Table]
Grant, ADARE-204 and ADARE-214
Grant, ADARE-204 and ADARE-214 [Member]
Grant, ADARE-204 and ADARE-214
Measurement Frequency [Domain]
Measurement Frequency [Domain]
Counterparty Name [Axis]
Counterparty Name [Axis]
Basis of Presentation and Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Current portion of contingent consideration
Asset Acquisition, Contingent Consideration, Current
Asset Acquisition, Contingent Consideration, Current
City Area Code
City Area Code
Royalty Investment Financing Agreement
Royalty Investment Financing Agreement [Member]
Royalty Investment Financing Agreement
Current liabilities
Liabilities, Current [Abstract]
License And Collaboration Revenue
License And Collaboration Revenue [Member]
License And Collaboration Revenue
Insider Trading Policies and Procedures Not Adopted
Insider Trading Policies and Procedures Not Adopted [Text Block]
Level 1
Fair Value, Inputs, Level 1 [Member]
Foreign currency translation adjustments
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Total current assets
Assets, Current
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Accrued expenses
Increase (Decrease) in Accrued Liabilities
Exercisable (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Lincoln Park Capital Fund, LLC
Lincoln Park Capital Fund, LLC [Member]
Lincoln Park Capital Fund, LLC
Weighted-average fair value of options granted (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Other Commitments [Axis]
Other Commitments [Axis]
Subsequent Event Type
Subsequent Event Type [Axis]
Measurement Input, Expected Term
Measurement Input, Expected Term [Member]
Income (loss) per common share:
Earnings Per Share [Abstract]
Equity [Abstract]
Equity [Abstract]
Contingent purchase price payments
Royalty Agreement, Contingent Purchase Price Payments
Royalty Agreement, Contingent Purchase Price Payments
Accumulated deficit
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Hard cap rate
Royalty Agreement, Hard Cap, Percentage
Royalty Agreement, Hard Cap, Percentage
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
General and administrative expenses
General and Administrative Expense
Issuable upon additional investment made number of securities called by warrants
Class Of Warrant Or Right, Initial Royalty Warrant Issued
Class Of Warrant Or Right, Initial Royalty Warrant Issued
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Aggregate Available
Trading Arrangement, Securities Aggregate Available Amount
Equity Awards Adjustments
Equity Awards Adjustments [Member]
Weighted average interest rate
Operating Lease, Weighted Average Discount Rate, Percent
Total operating lease liabilities
Operating Lease, Liability
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Reverse stock split adjustment
Adjustments to Additional Paid in Capital, Stock Split
Contraceptive product grant agreement
Contraceptive Product Grant Agreement [Member]
Contraceptive Product Grant Agreement
Milestone payments rate
Royalty Agreement, Milestone Payments, Percentage
Royalty Agreement, Milestone Payments, Percentage
Underlying Securities
Award Underlying Securities Amount
Exercised (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value
Exercised (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Amendment Flag
Amendment Flag
Entity Registrant Name
Entity Registrant Name
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Property Plant Equipment
Adjustment to Non-PEO NEO Compensation Footnote
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
Stock Appreciation Rights (SARs)
Stock Appreciation Rights (SARs) [Member]
Purchase And Registration Rights Agreement
Purchase And Registration Rights Agreement [Member]
Purchase And Registration Rights Agreement
DARE-LBT
DARE-LBT [Member]
DARE-LBT
Fair Value as of Grant Date
Award Grant Date Fair Value
Subsequent Events [Abstract]
Subsequent Events [Abstract]
Debt issuance cost
Debt Issuance Costs, Net
Sale of stock, number of shares issued (in shares)
Sale of Stock, Number of Shares Issued in Transaction
Level 2
Fair Value, Inputs, Level 2 [Member]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV [Domain]
Registration statement period
Sale Of Stock, Registration Statement Period
Sale Of Stock, Registration Statement Period
Recovery of Erroneously Awarded Compensation Disclosure [Line Items]
Issuance of common stock
Stock Issued During Period, Value, New Issues
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Restatement Determination Date:
Restatement Determination Date [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Title of 12(b) Security
Title of 12(b) Security
Common stock, $0.0001 par value; 240,000,000 shares authorized; 8,546,364 and 8,331,161 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
Common Stock, Value, Issued
Ovaprene
Ovaprene [Member]
Ovaprene
Share-based Payment Arrangement [Abstract]
Share-Based Payment Arrangement [Abstract]
Forfeited or expired (in usd per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Upfront license fee paid
Upfront License Fee, Amount Paid
Upfront License Fee, Amount Paid
Accounts payable
Increase (Decrease) in Other Accounts Payable
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]
Amount due upon execution
License And Services Agreement, Amount Payable Upon Execution
License And Services Agreement, Amount Payable Upon Execution
Cash flows from financing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]
Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding
Preferred Stock, Value, Issued
Net royalty payments rate
Royalty Agreement, Net Royalty Payments, Percentage
Royalty Agreement, Net Royalty Payments, Percentage
Number of Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Fair Value Measurement [Domain]
Fair Value Measurement [Domain]
Income (loss) per common share - basic (in usd per share)
Earnings Per Share, Basic
Supplemental investment payment
Royalty Agreement, Supplement Investment Payment
Royalty Agreement, Supplement Investment Payment
Aggregate net proceeds on sales of shares of common stock
Proceeds from Issuance of Common Stock
Cash paid for measurement of operating lease liabilities
Operating Lease, Payments
Deposits
Deposits Assets, Noncurrent
Adjustment To PEO Compensation, Footnote
Adjustment To PEO Compensation, Footnote [Text Block]
Award Timing MNPI Disclosure
Award Timing MNPI Disclosure [Text Block]
Remaining obligation
Contractual Obligation
Grant, DARE-PTB2
Grant, DARE-PTB2 [Member]
Grant, DARE-PTB2
Aggregate Pension Adjustments Service Cost
Aggregate Pension Adjustments Service Cost [Member]
Outstanding, Weighed Average Remaining Life in Years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms
Compensation Actually Paid vs. Other Measure
Compensation Actually Paid vs. Other Measure [Text Block]
Hennepin License Agreement
Hennepin License Agreement [Member]
Hennepin License Agreement
Schedule of Stock by Class [Table]
Stock, Class of Stock [Table]
Grant Awards
Grant Award [Text Block]
Grant Award [Text Block]
Total current liabilities
Liabilities, Current
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]
NICHD
NICHD [Member]
NICHD
Weighted average number of shares outstanding:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Total assets
Assets
First commercial sale amount
Milestone Payments, Contingent Amount, First Commercial Sale Amount
Milestone Payments, Contingent Amount, First Commercial Sale Amount
Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Payments on note payable
Repayments of Notes Payable
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Commitments and contingencies (Note 9)
Commitments and Contingencies
Phase I Segment
Phase I Segment [Member]
Phase I Segment
Termination Date
Trading Arrangement Termination Date
Class of Warrant or Right
Class of Warrant or Right [Domain]
Exercise Price (in usd per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total revenue
Revenues
2026
Lessee, Operating Lease, Liability, to be Paid, Year Two
Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Upon Achievement of Specified Development and Regulatory Milestones
Upon Achievement Of Specified Development And Regulatory Milestones [Member]
Upon achievement of specified development and regulatory milestones.
Entity Address, City or Town
Entity Address, City or Town
Debt Instrument
Debt Instrument [Axis]
Summary of Stock Option Activity
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Warrants
Warrants [Member]
Warrants
Reverse stock split adjustment (in shares)
Stock Issued During Period, Shares, Reverse Stock Splits
Stock-based compensation expense
Share-Based Payment Arrangement, Expense
Net income (loss)
Net income (loss)
Net Income (Loss) Attributable to Parent
Trading Arrangement:
Trading Arrangement [Axis]
Warrant, exercise price, decrease (in usd per share)
Warrant, Exercise Price, Decrease
Granted (in usd per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Pay vs Performance Disclosure, Table
Pay vs Performance [Table Text Block]
Business Acquisition
Business Acquisition [Axis]
XACIATO
XACIATO [Member]
XACIATO
Equity Awards Adjustments, Excluding Value Reported in Compensation Table
Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]
Synthetic
Synthetic [Member]
Synthetic
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]
Entity File Number
Entity File Number
Estimated fair value of warrants recorded in equity
Estimated Fair Value Of Warrants Recorded In Equity
Estimated Fair Value Of Warrants Recorded In Equity
Document Fiscal Year Focus
Document Fiscal Year Focus
Income Statement [Abstract]
Income Statement [Abstract]
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Two
July 2024 Financing
July 2024 Financing [Member]
July 2024 Financing
Debt Instrument, Name
Debt Instrument, Name [Domain]
Effect of exchange rate changes on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations
Name
Forgone Recovery, Individual Name
Remainder of 2024
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Operating lease weighted average remaining lease term
Operating Lease, Weighted Average Remaining Lease Term
Document Period End Date
Document Period End Date
Sale of Stock
Sale of Stock [Axis]
Contingent Consideration by Type [Axis]
Contingent Consideration by Type [Axis]
Award Timing MNPI Considered
Award Timing MNPI Considered [Flag]
Total future minimum lease payments
Lessee, Operating Lease, Liability, to be Paid
Deferred revenue - current
Increase (Decrease) in Deferred Revenue
Expired (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Insider Trading Arrangements [Line Items]
Royalty payments
Payments for Royalties
Outstanding Aggregate Erroneous Compensation Amount
Outstanding Aggregate Erroneous Compensation Amount
Other current assets
Increase (Decrease) in Other Current Assets
2027
Lessee, Operating Lease, Liability, to be Paid, Year Three
PEO Actually Paid Compensation Amount
PEO Actually Paid Compensation Amount
Forfeited or expired (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Warrants and rights outstanding (in shares)
Relative fair value of Initial Royalty Warrant
Warrants and Rights Outstanding
Adjustment to Compensation:
Adjustment to Compensation [Axis]
Reclassifications
Reclassification, Comparability Adjustment [Policy Text Block]
Restricted cash included in other non-current assets
Restricted Cash and Cash Equivalents, Noncurrent
Document Transition Report
Document Transition Report
Document Quarterly Report
Document Quarterly Report
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Entity Current Reporting Status
Entity Current Reporting Status
ADVA Tec Agreement
A D V A Tec Agreement [Member]
ADVA Tec agreement.
Accumulated deficit
Retained Earnings [Member]
Pension Adjustments Service Cost
Pension Adjustments Service Cost [Member]
Douglas License Agreement
Douglas License Agreement [Member]
Douglas License Agreement
Effective annual interest rate
Royalty Agreement, Effective Annual Interest Rate, Percentage
Royalty Agreement, Effective Annual Interest Rate, Percentage
Related Party
Related and Nonrelated Parties [Axis]
Basic (in shares)
Weighted Average Number of Shares Outstanding, Basic
Stock Price or TSR Estimation Method
Stock Price or TSR Estimation Method [Text Block]
Reverse Stock Split
Stockholders' Equity, Policy [Policy Text Block]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Executive Category:
Executive Category [Axis]
Name
Awards Close in Time to MNPI Disclosures, Individual Name
Canceled/forfeited (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Organon
Organon [Member]
Organon
Entity Filer Category
Entity Filer Category
Payment of additional consideration
Payment of Additional Consideration in Business Combination
Payment of Additional Consideration in Business Combination
Income Statement Location
Statement of Income Location, Balance [Domain]
Company Selected Measure Name
Company Selected Measure Name